Karyopharm Therapeutics earnings were -$62.5M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest KPTI earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$23.5M, down 23.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, KPTI reported annual earnings of -$76.4M, with -46.6% growth.
Karyopharm Therapeutics Earnings Reports & History FAQ
What were Karyopharm Therapeutics's earnings last quarter?
On KPTI's earnings call on Invalid Date, Karyopharm Therapeutics (NASDAQ: KPTI) reported Q1 2025 earnings per share (EPS) of -$2.77, up 42.89% year over year. Total KPTI earnings for the quarter were -$23.46 million. In the same quarter last year, Karyopharm Therapeutics's earnings per share (EPS) was -$4.85.
Is Karyopharm Therapeutics profitable or losing money?
As of the last Karyopharm Therapeutics earnings report, Karyopharm Therapeutics is currently losing money. Karyopharm Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$62.52 million, a 57.27% decrease year over year.
What was KPTI's earnings growth in the past year?
As of Karyopharm Therapeutics's earnings date in Invalid Date, Karyopharm Therapeutics's earnings has grown year over year. KPTI earnings in the past year totalled -$62.52 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.